CA2216055A1 - Milieu favorisant la survie des cellules secretrices d'insuline - Google Patents

Milieu favorisant la survie des cellules secretrices d'insuline Download PDF

Info

Publication number: CA2216055A1
Authority: CA; Canada
Prior art keywords: culture medium; medium; islet; islets; ngf
Prior art date: 1997-09-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2216055

Other languages

English (en)

Inventor

Lawrence Rosenberg

Dusica Maysinger

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

McGill University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-19

Filing date

1997-09-19

Publication date

1999-03-19

1997-09-19 Application filed by McGill University filed Critical McGill University

1997-09-19 Priority to CA 2216055 priority Critical patent/CA2216055A1/fr

1998-09-17 Priority to AU91498/98A priority patent/AU9149898A/en

1998-09-17 Priority to PCT/CA1998/000887 priority patent/WO1999015625A1/fr

1998-09-17 Priority to CA002304381A priority patent/CA2304381A1/fr

1999-03-19 Publication of CA2216055A1 publication Critical patent/CA2216055A1/fr

2002-05-06 Priority to US10/138,517 priority patent/US6562620B2/en

Status Abandoned legal-status Critical Current

Links

210000004153 islets of langerhan Anatomy 0.000 title claims abstract description 24
230000004083 survival effect Effects 0.000 title claims abstract description 18
239000001963 growth medium Substances 0.000 claims abstract description 23
230000000694 effects Effects 0.000 claims abstract description 12
239000003102 growth factor Substances 0.000 claims abstract description 12
230000006909 anti-apoptosis Effects 0.000 claims abstract description 3
230000001737 promoting effect Effects 0.000 claims abstract description 3
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 24
239000002609 medium Substances 0.000 claims description 13
102000004877 Insulin Human genes 0.000 claims description 12
108090001061 Insulin Proteins 0.000 claims description 12
229940125396 insulin Drugs 0.000 claims description 12
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 10
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 8
239000003018 immunosuppressive agent Substances 0.000 claims description 7
229960003444 immunosuppressant agent Drugs 0.000 claims description 6
230000001861 immunosuppressant effect Effects 0.000 claims description 5
102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 4
108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 4
230000003389 potentiating effect Effects 0.000 claims description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 claims description 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 2
102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 2
239000012980 RPMI-1640 medium Substances 0.000 claims 1
230000006907 apoptotic process Effects 0.000 description 14
108010025020 Nerve Growth Factor Proteins 0.000 description 12
102000015336 Nerve Growth Factor Human genes 0.000 description 12
229940053128 nerve growth factor Drugs 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
210000000496 pancreas Anatomy 0.000 description 10
238000002054 transplantation Methods 0.000 description 10
206010012601 diabetes mellitus Diseases 0.000 description 8
238000002955 isolation Methods 0.000 description 6
201000001421 hyperglycemia Diseases 0.000 description 5
108060008539 Transglutaminase Proteins 0.000 description 4
230000024245 cell differentiation Effects 0.000 description 4
239000012634 fragment Substances 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
102000003601 transglutaminase Human genes 0.000 description 4
102000003745 Hepatocyte Growth Factor Human genes 0.000 description 3
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
206010062016 Immunosuppression Diseases 0.000 description 3
102000013275 Somatomedins Human genes 0.000 description 3
108010009583 Transforming Growth Factors Proteins 0.000 description 3
102000009618 Transforming Growth Factors Human genes 0.000 description 3
230000001640 apoptogenic effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
230000006882 induction of apoptosis Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
238000003782 apoptosis assay Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
230000008175 fetal development Effects 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000009707 neogenesis Effects 0.000 description 2
230000003076 paracrine Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000005522 programmed cell death Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001228 trophic effect Effects 0.000 description 2
238000013042 tunel staining Methods 0.000 description 2
102000004631 Calcineurin Human genes 0.000 description 1
108010042955 Calcineurin Proteins 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
101100226058 Dictyostelium discoideum erkB gene Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
101710111747 Peptidyl-prolyl cis-trans isomerase FKBP12 Proteins 0.000 description 1
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
101710111682 Peptidyl-prolyl cis-trans isomerase FKBP1A Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
206010060872 Transplant failure Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000002153 concerted effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011833 dog model Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
210000003890 endocrine cell Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000002608 insulinlike Effects 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000006371 metabolic abnormality Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000002276 neurotropic effect Effects 0.000 description 1
230000001019 normoglycemic effect Effects 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
210000000277 pancreatic duct Anatomy 0.000 description 1
210000004923 pancreatic tissue Anatomy 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
230000029537 positive regulation of insulin secretion Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229940072288 prograf Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000002488 pyknotic effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000026267 regulation of growth Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/22—Coculture with; Conditioned medium produced by pancreatic cells

Landscapes

Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 2216055 1997-09-19 1997-09-19 Milieu favorisant la survie des cellules secretrices d'insuline Abandoned CA2216055A1 (fr)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
CA 2216055 CA2216055A1 (fr)	1997-09-19	1997-09-19	Milieu favorisant la survie des cellules secretrices d'insuline
AU91498/98A AU9149898A (en)	1997-09-19	1998-09-17	A medium to promote islet cell survival
PCT/CA1998/000887 WO1999015625A1 (fr)	1997-09-19	1998-09-17	Milieu favorisant la survie des cellules insulaires
CA002304381A CA2304381A1 (fr)	1997-09-19	1998-09-17	Milieu favorisant la survie des cellules insulaires
US10/138,517 US6562620B2 (en)	1997-09-19	2002-05-06	Medium to promote islet cell survival

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2216055 CA2216055A1 (fr)	1997-09-19	1997-09-19	Milieu favorisant la survie des cellules secretrices d'insuline

Publications (1)

Publication Number	Publication Date
CA2216055A1 true CA2216055A1 (fr)	1999-03-19

Family

ID=4161504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2216055 Abandoned CA2216055A1 (fr)	1997-09-19	1997-09-19	Milieu favorisant la survie des cellules secretrices d'insuline

Country Status (3)

Country	Link
AU (1)	AU9149898A (fr)
CA (1)	CA2216055A1 (fr)
WO (1)	WO1999015625A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1248640A1 (fr) *	2000-01-20	2002-10-16	Diatranz Limited	Preparation et xenotransplantation d'ilots de porc

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5587309A (en) *	1994-04-29	1996-12-24	The United States Of America As Represented By The Department Of Health And Human Services	Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
DE19540080A1 (de) *	1995-10-27	1997-04-30	Bayer Ag	3-Aryl-5-halogen-pyron-Derivate

1997
- 1997-09-19 CA CA 2216055 patent/CA2216055A1/fr not_active Abandoned
1998
- 1998-09-17 AU AU91498/98A patent/AU9149898A/en not_active Abandoned
- 1998-09-17 WO PCT/CA1998/000887 patent/WO1999015625A1/fr active Application Filing

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1248640A1 (fr) *	2000-01-20	2002-10-16	Diatranz Limited	Preparation et xenotransplantation d'ilots de porc
EP1248640A4 (fr) *	2000-01-20	2003-05-21	Diatranz Ltd	Preparation et xenotransplantation d'ilots de porc
US7122177B2 (en)	2000-01-20	2006-10-17	Diabcell Pty Ltd.	Preparation and xenotransplantation of porcine islets
US7323323B2 (en)	2000-01-20	2008-01-29	Diabell Pty Ltd.	Preparation and xenotransplantation of porcine islets

Also Published As

Publication number	Publication date
WO1999015625A1 (fr)	1999-04-01
AU9149898A (en)	1999-04-12

Legal Events

Date	Code	Title	Description
1999-12-22	FZDE	Dead

Publication	Publication Date	Title
Gamble et al.	2018	The journey of islet cell transplantation and future development
US6638765B1 (en)	2003-10-28	Platform for the differentiation of cells
Pellegrini et al.	1997	Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium
US20040132183A1 (en)	2004-07-08	Methods and compositions for expanding and differentiating insulin-producing cells
US20060040385A1 (en)	2006-02-23	Cultured human pancreatic islets, and uses thereof
NO320713B1 (no)	2006-01-23	Farmasoytisk preparat som omfatter Sertoli-celler og celler som produserer en biologisk faktor, seksjonert sett med beholdere for cellene, produktartikkel som omfatter et embaleringsmateriale med Sertoli-celler og fremgangsmate for okning av utvinning og profilering av celler ex vivo.
US20080318202A1 (en)	2008-12-25	Chimeric pancreas
CN112980771A (zh)	2021-06-18	一种制备胰腺beta细胞的方法及其应用
US20050037490A1 (en)	2005-02-17	Medium for preparing dedifferentiated cells
CA2216055A1 (fr)	1999-03-19	Milieu favorisant la survie des cellules secretrices d'insuline
US6562620B2 (en)	2003-05-13	Medium to promote islet cell survival
US20010000324A1 (en)	2001-04-19	Promotion of cell differentiation by initially passaged cells
CA2304381A1 (fr)	1999-04-01	Milieu favorisant la survie des cellules insulaires
Abban-Mete et al.	2013	The effects of epidermal growth factor on pancreas in alloxan-diabetic rats: an ultrastructural study
KR100354931B1 (ko)	2002-10-05	췌도의 대량 배양증식 및 증식한 췌도에 의한 당뇨치료방법
Pueyo et al.	1995	A method for obtaining monodispersed cells from isolated porcine islets of Langerhans
Maeno et al.	2006	Islet-like cell clusters: viability, cell types, and subretinal transplantation in pancreatectomized cats
AU4544299A (en)	1999-12-13	Promotion of cell differentiation by initially passaged cells
CA2567823A1 (fr)	2004-12-09	Plate-forme in vitro de criblage d'agents inducteurs de la neogenese des ilots de langerhans
Djordjevic et al.	2004	Human fetal islet transplantation in type 1 diabetic patients: comparison of metabolic effects between single and multiple implantation regimens
WO2004037277A2 (fr)	2004-05-06	Procede et composition pour la regression du diabete et utilisations correspondantes
WAN-CHUN et al.	0	TRANSFIGURATION AND RESURRECTION OF THE BETA-CELL